What is IPO Grey Market Premium (GMP)?

IPO Grey Market Premium (GMP) is an unofficial, over-the-counter premium over the issue price that dealers and investors pay prior to official listing on NSE/BSE.

How is estimated IPO listing price determined?

Estimated Listing Price = Cut-off / Issue Price + Current Grey Market Premium (GMP). For example, an issue price of ₹100 with ₹40 GMP yields an estimated listing price of ₹140 (+40%).

What is Kostak rate in an IPO?

Kostak rate is the fixed profit earned by selling an IPO application before allotment, irrespective of whether the application is allotted shares or not.

What is Subject to Sauda in IPO trading?

Subject to Sauda is an informal contract where payment is made only if the seller receives share allotment in the IPO.

Is IPO Grey Market Premium (GMP) regulated by SEBI?

No. Grey Market transactions are non-exchange over-the-counter commitments and are not officially regulated or endorsed by SEBI. Investors should treat GMP as an informal sentiment indicator.

What is the current subscription status of Windlas Biotech Limited IPO?

Windlas Biotech Limited IPO has received a total subscription of 0.00 times overall.

IPO GreyPremiumLIVE

Grey Market Intelligence

Windlas Biotech Limited

ListedMainboard

Healthcare & Pharmaceuticals · NSE / BSE

Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.

Price Band

₹448 – ₹460

Issue Size

₹402 Cr

Lot Size

30 shares

GMP

₹80

+17.4%

Est. Listing

₹540

at current GMP

Subscribed

—

Open

4 Aug 2021

6 Aug 2021

Allotment

11 Aug 2021

Refund

12 Aug 2021

Demat Credit

13 Aug 2021

Listing

16 Aug 2021

Last updated 12 days ago

Overview Live GMP Subscription Status Allotment Status Filing Documents

Overall Subscription

0.00x

Total Demand

QIB Multiplier

0.00x

Institutions & Funds

NII / HNI

0.00x

High Net-Worth

Retail (RII)

0.00x

Individual Bidders

Category-Wise Subscription Breakup

Live bidding breakdown by institutional, non-institutional, and retail investors

Total 0.00x

Category	Shares Offered	Shares Applied / Bid	Times Subscribed
Qualified Institutional (QIB)	4,369,565	—	0.00x
Non-Institutional (NII / HNI)	1,310,870	—	0.00x
Retail Individual (RII)	3,058,696	—	0.00x
Total	8,739,131	0	0.00x

Application-Wise Breakup

Total unique applications received across retail and HNI tranches

Apps 1.00x

Category	Applications Reserved	Applications Received	Times Subscribed
Retail (RII)	101,957	101,957	1.00x
HNIs (10L +)	652	652	1.00x
HNIs (2-10L)	3,121	3,121	1.00x
Total Applications	105,730	105,730	1.00x

Day-Wise Subscription Progress

Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.

About Windlas Biotech Limited Public Issue & Market Profile

Windlas Biotech Limited is bringing an initial public offering (IPO) in the Healthcare & Pharmaceuticals sector with an aggregate issue size of ₹402 Crores. The shares are offered at a price band of ₹448 to ₹460 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.

Bidding & Quota Instructions:

The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.

Allotment Reconciliation Schedule:

Following the close of bidding on 2021-08-06, the basis of allotment is scheduled to be finalized on 2021-08-11. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.

Frequently Asked Questions

What is Windlas Biotech Limited IPO GMP today?

The latest Grey Market Premium (GMP) for Windlas Biotech Limited IPO is ₹80 per equity share. Based on the upper price band of ₹448 to ₹460 per equity share, the estimated listing price is ₹540 (+17.4% expected listing gain).

What is the expected profit per lot for Windlas Biotech Limited IPO?

With a lot size of 30 shares and current GMP of ₹80, the expected profit per application lot is approx ₹2,400 (+17.4% gain). Minimum application cost is approx ₹13,800.

What is the issue size and price band for Windlas Biotech Limited IPO?

The Windlas Biotech Limited IPO aggregate issue size is ₹402 Crores with an equity price band set at ₹448 to ₹460 per equity share. The retail lot size is 30 shares requiring a minimum capital outlay of approx. ₹13,800.

How can I check Windlas Biotech Limited IPO live subscription demand?

Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 0.00x (Retail: 0.00x, QIB: 0.00x, NII: 0.00x). You can track live multiples directly on our dedicated subscription page.

Where and when will Windlas Biotech Limited IPO allotment status be published?

The basis of allotment will be published on the official registrar portal (Link Intime India Private Limited) and the BSE status verification website on or around 2021-08-11. Investors can verify status using PAN card or application number.

When is the listing date for Windlas Biotech Limited IPO?

Windlas Biotech Limited shares are scheduled to list on NSE and BSE on 2021-08-16.